VJDementia
VJDementia
  • 1 258
  • 624 888
The spread of oligomeric tau through synapses in Alzheimer's disease
Tara Spires-Jones, PhD, University of Edinburgh, Edinburgh, Scotland, discusses her research on the spread of oligomeric tau through synapses in Alzheimer's disease (AD). Using an adapted ray tomography technique combined with immunohistochemistry and microscopy, her study identified oligomeric tau accumulation in both the temporal and occipital lobes, with evidence suggesting tau spreads through synaptic connections. Additionally, research on living human brain slices from patients with progressive supranuclear palsy (PSP) revealed that oligomeric tau uptake by post-synaptic sites leads to astrocyte-induced synapse loss. This research aims to contribute to the understanding of tau propagation throughout the brain to develop treatments that could halt its spread and treat AD. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
zhlédnutí: 737

Video

Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer's disease
zhlédnutí 20Před měsícem
In a recent study, Isabel Castanho, PhD, Beth Israel Deaconess Medical Center, Boston, MA, described the relevance of an imbalance in excitatory and inhibitory neurons in cognitive resilience. Single cell transcriptomics revealed a reduced proportion of vulnerable somatostatin-expressing inhibitory neurons in AD but not in resilience, as well as an increase in specific excitatory populations in...
The impact of meditation on mental health and well-being in aging
zhlédnutí 14Před měsícem
Gaël Chételat, PhD, HDR , Inserm, Université de Caen-Normandie, Caen, France, discusses her study on the impact of long-term meditation on brain structure and function. She highlights how in patients with subjective cognitive decline, meditation was able to reduce anxiety. While no significant differences in brain structure and function were seen in the long-term meditation group compared to co...
Introducing novel AD biomarkers into clinical practice: how close are we?
zhlédnutí 16Před měsícem
The field of biomarkers for Alzheimer’s disease (AD) has grown rapidly in recent years, particularly with novel blood-based biomarkers such as phosphorylated tau181 (p-tau181) and p-tau217. Marta Milà-Alomà, PhD, Northern California Institute for Research and Education (NCIRE), San Francisco, CA, provides her perspective on the remaining challenges to be overcome before novel biomarkers can be ...
How society needs to be made ready to treat Alzheimer’s disease
zhlédnutí 45Před měsícem
Bengt Winblad, MD, PhD, Karolinska Institutet, Solna, Sweden, provides insights into how society needs to be made ready for Alzheimer’s disease modifying therapies. He highlights that improved early diagnosis methods could lead to an influx of patients, and the importance of doctors following treatment guidelines. Prof. Winblad acknowledges that GPs and memory clinics will both be under pressur...
Inspiring advances in research through scientific meetings
zhlédnutí 13Před měsícem
As Executive Organizer of AD/PD™, Manfred Windisch, PhD, NeuroScios GmbH, Graz, Austria, discusses the importance of the conference in inspiring advances for Alzheimer’s disease. He highlights the growth of the conference, and its aim to attract more young scientists and clinicians, with more than 40% of scientists in attendance below the age of 40. This interview took place at the AD/PD™ 2024 ...
The potential of brain-derived tau as a neurodegeneration biomarker
zhlédnutí 31Před měsícem
Bjørn-Eivind Kirsebom, PhD, University Hospital of North Norway, Tromsø, Norway, discusses brain-derived (BD) tau as a biomarker in Alzheimer’s disease (AD). BD-tau has emerged recently as an AD-specific marker of neurodegeneration. Unlike NfL, BD-tau uniquely reflects the extent of neurodegeneration in patients with AD, showing high accuracy to differentiate AD from other dementias. A recent s...
Metabolome-wide association studies in Alzheimer's disease
zhlédnutí 16Před měsícem
Genome-wide association studies (GWAS) in Alzheimer’s disease (AD) have identified many risk loci, however the mechanisms by which these confer susceptibility to AD are poorly understood. Rui Pinto, PhD, Imperial College London, London, UK, discusses results from a metabolome-wide association study (MWAS) to detect metabolic features associated with genetic variants for AD, which revealed that ...
Interactions between Aβ and tau proteins in Alzheimer’s disease
zhlédnutí 15Před měsícem
Gaël Chételat, PhD, HDR, Inserm, Université de Caen-Normandie, Caen, France, discusses the interaction of amyloid beta (Aβ) and tau proteins in Alzheimer’s disease. Aβ has not been shown to be responsible for the specificity of the topography of tau, but does interact with tau to promote and accelerate its propagation. Dr Chételat highlights the importance of conducting more longitudinal studie...
Sex differences in Alzheimer's disease plasma biomarkers
zhlédnutí 28Před měsícem
While sex differences in the risk and presentation of Alzheimer’s disease (AD) are well-studied, little is known about how these extend to plasma biomarkers. Marta Milà-Alomà, PhD, Northern California Institute for Research and Education (NCIRE), San Francisco, CA, discusses recent research investigating potential sex differences in plasma biomarkers in cognitively unimpaired (CU) individuals a...
Polygenic risk scores for Alzheimer's disease in relation to cognitive change
zhlédnutí 30Před měsícem
Jenna Najar, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden & Amsterdam University Medical Center, Amsterdam, Netherlands talks about her research on polygenic risk scores (PRS) in Alzheimer’s disease (AD) in relation to cognitive change. Over 900 older individuals without dementia were examined at age 70, 75, 79, and 85 years to track cognitive function. They aimed to determine i...
Tau-targeted therapy landscape in Alzheimer’s disease
zhlédnutí 33Před měsícem
Bengt Winblad, MD, PhD, Karolinska Institutet, Solna, Sweden, discusses his thoughts on the importance of combined therapies targeting amyloid- and tau-pathology in treating Alzheimer’s disease. He also discusses recent advances in the tau-targeted therapy research landscape in Europe, including the use of active immunotherapy. Prof. Wingblad highlights an example treatment where patients are i...
Next steps in anti-amyloid immunotherapy
zhlédnutí 21Před měsícem
Robert Vassar, PhD, Feinberg School of Medicine, Northwestern University, Chicago, IL, highlights the questions that most need answering regarding anti-amyloid immunotherapies. One important question is when to treat with these agents. With antibodies slowing down Alzheimer’s disease progression but not stopping the disease, trials are now looking into delaying or even preventing its onset alto...
Markers of of tau pathology in Alzheimer’s disease
zhlédnutí 18Před měsícem
Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden, explains that plasma p-tau markers appear to be more indicative of amyloid traces than tau pathology specifically, highlighting the need for discovery of blood biomarkers that solely indicate tau pathology. He also highlights how some plasma biomarkers, like neurofilament light chain, can also have increased levels caused by other dise...
Updates on tau topography and propagation
zhlédnutí 24Před měsícem
Gaël Chételat, PhD, HDR, Inserm, Université de Caen-Normandie, Caen, France, discusses her talk about tau topography and propagation. She explains that understanding the propagation of tau is crucial in preventing and delaying Alzheimer's disease (AD), as it is the primary driver of neurodegeneration. Recent advancements in neuroimaging and mathematical modeling have provided insights into pred...
Metabolomics analysis of the FINGER trial
zhlédnutí 10Před měsícem
Metabolomics analysis of the FINGER trial
The direction of disease-modifying therapeutic development in Alzheimer’s disease
zhlédnutí 68Před měsícem
The direction of disease-modifying therapeutic development in Alzheimer’s disease
Subtyping mixed primary progressive aphasia
zhlédnutí 25Před měsícem
Subtyping mixed primary progressive aphasia
Shaping future care: biomarker advances in Alzheimer’s Disease
zhlédnutí 77Před měsícem
Shaping future care: biomarker advances in Alzheimer’s Disease
Challenges in fluid biomarker development in Alzheimer's disease research
zhlédnutí 154Před 4 měsíci
Challenges in fluid biomarker development in Alzheimer's disease research
Neuroprotective effects of transcription factor NRF2 in Alzheimer’s disease mice models
zhlédnutí 77Před 4 měsíci
Neuroprotective effects of transcription factor NRF2 in Alzheimer’s disease mice models
How are blood-based biomarkers currently used in Alzheimer’s disease?
zhlédnutí 157Před 4 měsíci
How are blood-based biomarkers currently used in Alzheimer’s disease?
ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease
zhlédnutí 134Před 4 měsíci
ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease
Distinguishing between late-onset primary psychiatric disorders and dementia
zhlédnutí 113Před 4 měsíci
Distinguishing between late-onset primary psychiatric disorders and dementia
Promise of tau-PET imaging for Alzheimer's disease
zhlédnutí 124Před 4 měsíci
Promise of tau-PET imaging for Alzheimer's disease
Prognostic accuracy of plasma NfL to predict Alzheimer’s disease dementia
zhlédnutí 46Před 4 měsíci
Prognostic accuracy of plasma NfL to predict Alzheimer’s disease dementia
Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease
zhlédnutí 74Před 4 měsíci
Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease
Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia
zhlédnutí 45Před 4 měsíci
Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia
Examining plasma vs. CSF p-tau217 in preclinical and prodromal Alzheimer’s disease
zhlédnutí 129Před 4 měsíci
Examining plasma vs. CSF p-tau217 in preclinical and prodromal Alzheimer’s disease
How goes audiovisual gamma stimulation provide benefit in Alzheimer's disease?
zhlédnutí 51Před 4 měsíci
How goes audiovisual gamma stimulation provide benefit in Alzheimer's disease?